Industry News

Haemacure obtains U.S. patent for a Fibrin-based Biomaterial Adhesive

Published on 2003-02-21. Author : SpecialChem


Corporation Haemacure announced that the United States Patent and Trademark Office has granted the Corporation patent no. 6,503,527, entitled "Fibrin sealants or adhesives comprising a hyaluronic acid derivative material". The invention of Dr. Elaine Whitmore and Marc Paquin relates to a fibrin glue composition comprised of biomaterials, including a hyaluronic acid derivative, chitin and a chitosan derivative, to which fibrinogen and thrombin are added.

This composition can be placed directly on, around or within an internal wound site and is fully absorbed by the body. "Thanks to these biomaterials blood absorbing property, their absorption by the body and their flexibility, the future products can serve as anti-adhesion agents. Also, these products will eventually allow surgeons to stop profuse internal bleeding, especially during soft tissue surgery. The market, estimated at close to US$1 billion worldwide, represents a major future growth avenue for Haemacure," stated Marc Paquin, President and CEO of Haemacure.

"The granting of this patent is an important step forward for the Corporation since it will allow us to pursue partnering opportunities to develop and eventually obtain FDA approval of such an advantageous product," concluded Mr. Paquin.

Haemacure Corporation is a Canadian company specializing in the development and commercialization of innovative biological adhesives, biomaterials and surgical devices for the acute surgical wound care market. It also operates sales and marketing, clinical and regulatory offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under the stock symbol HAE on the Toronto Stock Exchange.

Source: Haemacure Corporation

Improve your performance with water soluble epoxy compounds
Naphthenic Oils For Better Adhesion
Back to Top